A Phase 2 Biomarker-Enriched Study of TH-302 in Subjects with Advanced Melanoma
A study for patients with advanced melanoma using study drug TH-302
Sponsor: Threshold Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAO5759
U.S. Govt. ID: NCT01864538
Contact: Richard Carvajal: 646-317-6041 / carvajalr@columbia.edu
Additional Study Information: The purpose of this study is to gather information on the safety of TH-302 and its effect on your cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about your specific cancer such as the level of oxygen that is present. This may help us understand which patients may be more likely to be helped by TH-302.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Do you have a documented history of malignant melanoma that is recurrent or metastatic and uncurable by surgery or other means? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal
carvajalr@columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE